Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies
This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…
CertaraFebruary 6, 2025
How do you see advances in personalized medicine reshaping patient care, and what are the key challenges and opportunities ahead?
Discover how advances in personalized medicine are reshaping patient care, and why biosimulation will become…
CertaraJanuary 31, 2025
Understanding Variability in CAR-T Cell Therapy Kinetics
Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…
CertaraJanuary 23, 2025
Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region
The integration of MID3 offers a transformative opportunity for the MENA region to advance pharmaceutical…
CertaraJanuary 14, 2025
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)
In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…
CertaraJanuary 9, 2025
From Research to Real-World Impact: A Model Informed Drug Development (MIDD) Framework to Support Understudied Populations
SVP, Client and Regulatory Strategy, Certara Dr. Karen Rowland Yeo is Senior Vice-President, Client &…
CertaraJanuary 3, 2025
Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development
At the 2024 AAPS PharmSci 360 conference, Bioanalysis Zone interviewed Piet van der Graaf, Senior…
CertaraDecember 10, 2024
Advancing pharmacometrics in Africa – Transition from capacity development toward job creation
This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…
CertaraDecember 9, 2024
